Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02317354 · ClinicalTrials.gov registry record

People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial

A clinical trial, sponsored by National Eye Institute (NEI).

Completed
Registry status
13
Enrollment target

NCT02317354 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 13 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02317354 has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
13 participants
Enrollment target

Study Summary

Background: -X-linked retinoschisis (XLRS) is an inherited eye condition. Researchers want to learn more about how people with XLRS choose to take part in research studies. They hope to find ways to help other people make decisions about joining early phase trials Objective: -To learn more about how people think and feel about taking part in early phase research. Eligibility: -Adults age 18 or older with diagnosed XLRS. They must be eligible to be screened for a Phase I/II ocular gene transfer clinical trial. Design: * Participants will be screened for the XLRS gene transfer study. They will be interviewed: * Eligible participants who join the study - before the gene transfer procedure, then 3 months and 12 months after it. * Eligible participants who do not join the study - after their screening visit and 3 months and 12 months later. \<TAB\>- Participants who are screened but ineligible - after their screening visit. \<TAB\>- Participants who choose not to be screened - at the time they make the decision and 1 year later. * Interviews will ask for the participants thoughts about the clinical trial and why they chose to take part or not. The interviews will be recorded. * On the day of interview 1, participants will fill out a survey about their mood and personality. * On the days of interviews 2 and 3, participants will fill out a survey about their mood. * Interviews may be done in person or by phone. Surveys can be done online or through the mail. Or they can be done in person at the NIH Clinical Center.

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2014-12-13
Est. Completion 2017-11-20

Sponsor

National Eye Institute (NEI)

221 total trials

What the Registry Record Tells You About NCT02317354

The ClinicalTrials.gov registry entry for NCT02317354 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02317354 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02317354 about?

NCT02317354 is a clinical study titled "People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial". Background: -X-linked retinoschisis (XLRS) is an inherited eye condition. Researchers want to learn more about how people with XLRS choose to take part in research studies. They hope to find ways to help other people make decisions about joining early phase trials Objective: -To learn more about ...

What is the current status of trial NCT02317354?

This trial is currently completed. The enrollment target is 13 participants. The study started on 2014-12-13. Estimated completion is 2017-11-20.

Who is sponsoring clinical trial NCT02317354?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.